Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
about
The history of neuromyelitis opticaNeuromyelitis optica spectrum disorders: An updateAquaporin-4 autoimmunityChallenges and opportunities in designing clinical trials for neuromyelitis opticaImmunology of neuromyelitis optica: a T cell-B cell collaborationTreatment of neuromyelitis optica: state-of-the-art and emerging therapiesImaging Surrogates of Disease Activity in Neuromyelitis Optica Allow Distinction from Multiple SclerosisCurrent concept of neuromyelitis optica (NMO) and NMO spectrum disorders.Weighing in on autoimmune disease: Big data tip the scale.Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography.Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status.Neuromyelitis optica: clinical features, immunopathogenesis and treatment.Magnetic resonance imaging in neuromyelitis optica.Seronegative Neuromyelitis Optica Spectrum--the challenges on disease definition and pathogenesis.Longitudinally extensive transverse myelitis in neuromyelitis optica: a prospective study of 13 Caucasian patients and literature review.Experimental models of neuromyelitis optica.Differential diagnosis of neuromyelitis optica spectrum disorders.On the contribution of Thomas Clifford Allbutt, F.R.S., to the early history of neuromyelitis optica.The treatment of neuromyelitis optica.Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis.Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.The Correlation between Aquaporin-4 Antibody and the Visual Function of Patients with Demyelinating Optic Neuritis at Onset.Demographic and clinical features of neuromyelitis optica: A review.Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositivepatients in a Chinese population.Aquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMOMyasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patientsNeuromyelitis optica (NMO) and autoimmune thyroiditis.Impact of the anti-aquaporin-4 autoantibody on inner retinal structure, function and structure-function associations in Japanese patients with optic neuritisAutoimmune thyroiditis associated with neuromyelitis optica (NMO)Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS.Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report.Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatusIdiopathic acute transverse myelitis: outcome and conversion to multiple sclerosis in a large series.Different Phenotypes at Onset in Neuromyelitis Optica Spectrum Disorder Patients with Aquaporin-4 AutoimmunityA clinical and radiological profile of neuromyelitis optica and spectrum disorders in an Indian cohort.A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica).Novel advances in the diagnosis and treatment of neuromyelitis optica: is there a need to redefine the gold standard?Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK.
P2860
Q21245248-B9B1C9FE-762D-4320-9D8C-DAE40FA4DB08Q26779913-33977C8D-75A8-4FF2-B934-E26F4A878C13Q26799559-A2EC68C8-A1BA-40FB-B13D-B8F401983989Q26999708-E1D80032-0522-4051-A62C-4E70093C148BQ27016045-E121E235-C51D-49BE-AF43-80699D7252F6Q28245749-C20FB5B9-175A-4F55-BEBC-32FF8CC6C649Q28267527-8617F17D-5184-43BE-9B3B-30BE5C94C6FBQ30577078-F26FBE81-6089-41E4-87CF-7938A8B5CB6CQ30587275-0062928B-7F2F-49C8-A126-FBACAB2CCFAAQ30649660-76B5BB00-1029-4249-8DA1-D4F24975FE47Q30676331-9294D2B3-E65A-4B7C-8B4F-6F83BD1F8896Q30785267-7A498F8F-133F-4EFC-8A79-629E7AECE1F4Q30820823-65FA7638-7A2D-482D-A279-6100C9D9EF2AQ30833332-82D1ED6C-3611-46C5-AD9A-895BEE151056Q30945169-68D54B77-E909-49A2-A1C9-64B5D7E1877DQ33785380-201B15F9-6A4A-41B6-AB8F-6A1D2D4DA8E9Q33812063-883853B8-C57C-4FEA-9F8B-C4C53A2925C8Q34287184-6DDAAB96-249E-4AC9-8C45-A156EFB76091Q34399291-3A06C3E0-C534-42DE-8B3C-EAADC47B9449Q34431835-1BEF98D8-3E1B-46E5-9763-17C87F0E3805Q35052199-76AD35A7-E1E3-4490-8A8F-019E99B4BEBAQ35072715-787037B7-6263-4D77-8096-D49D6D897D30Q35640735-0F6E9C46-26E7-463D-8CFB-E58F97962789Q35718428-93C5A896-14CF-4290-97F5-5EB531CB70BCQ35763927-35ADDE28-EC6C-40A3-B13B-95895856A7E8Q35764733-178D659B-FFE2-4704-A3AD-34FF8F789DADQ35948555-34F31C5A-C1BC-4D1B-A289-788A262B245EQ36226577-08C9CEA5-A60A-4F30-9EB2-D1136A50919AQ36281303-D9009D2C-B279-499D-AD6B-F668E386F752Q36291868-29A91EBA-4467-4FD7-8BA9-1A86196C2E23Q36303835-0BE29BB4-C28F-4959-9CE3-5F966452B46BQ36515512-35102387-9352-44ED-8248-CDC15E519A82Q36521281-D15D80F7-2C75-48DC-8358-AFD2D652C544Q36827205-BDFE3BD9-C7C2-4BED-ABC0-3A3D8BD8BEB9Q37376639-AF15AC04-1F65-47DB-9E6B-1833BCB43AE2Q37670455-B77AA424-DAD4-4A3F-8F23-3C2884166B6FQ37712153-F830EB1B-06E2-40F9-AB88-0742D128846BQ38074625-4B7AA955-7329-40CD-833D-4855C8A90591Q38152822-B82BAC90-BD7B-4DB7-BEF2-C1D47BE0927EQ38197504-73087D9C-A585-4C8C-8970-752896E1F497
P2860
Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Prognostic factors and disease ...... the United Kingdom and Japan.
@en
type
label
Prognostic factors and disease ...... the United Kingdom and Japan.
@en
prefLabel
Prognostic factors and disease ...... the United Kingdom and Japan.
@en
P2093
P2860
P356
P1433
P1476
Prognostic factors and disease ...... the United Kingdom and Japan.
@en
P2093
Benjamin McNeillis
Ichiro Nakashima
Jithin George
Joanna Kitley
Kazuo Fujihara
Liene Elsone
M Isabel Leite
Mark Woodhall
Mike Boggild
P2860
P304
P356
10.1093/BRAIN/AWS109
P407
P577
2012-05-09T00:00:00Z